Cargando…

OGG1 Inhibition Triggers Synthetic Lethality and Enhances The Effect of PARP Inhibitor Olaparib in BRCA1-Deficient TNBC Cells

BACKGROUND: PARP1 plays a critical role in the base excision repair (BER) pathway, and PARP1 inhibition leads to specific cell death, through a synthetic lethal interaction, in the context of BRCA1/2 deficiency. To date, up to five different PARP inhibitors (PARPi), have been approved, nevertheless,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baquero, Juan Miguel, Marchena-Perea, Erik, Mirabet, Rocío, Torres-Ruiz, Raúl, Blanco-Aparicio, Carmen, Rodríguez-Perales, Sandra, Helleday, Thomas, Benítez-Buelga, Carlos, Benítez, Javier, Osorio, Ana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9127384/ https://www.ncbi.nlm.nih.gov/pubmed/35619904 http://dx.doi.org/10.3389/fonc.2022.888810

Ejemplares similares

Molecular insights into the OGG1 gene, a cancer risk modifier in BRCA1 and BRCA2 mutations carriers
por: Benitez-Buelga, Carlos, et al.
Publicado: (2016)

Synthetic switches of OGG1 control initiation of base excision repair and offer new treatment strategies
por: Benitéz‐Buelga, Carlos, et al.
Publicado: (2022)

Small molecule inhibitor of OGG1 blocks oxidative DNA damage repair at telomeres and potentiates methotrexate anticancer effects
por: Baquero, Juan Miguel, et al.
Publicado: (2021)

TRIM21 mediates the synergistic effect of Olaparib and Sorafenib by degrading BRCA1 through ubiquitination in TNBC
por: Huang, Ning, et al.
Publicado: (2023)

OGG1 Inhibitor TH5487 Alters OGG1 Chromatin Dynamics and Prevents Incisions
por: Hanna, Bishoy M. F., et al.
Publicado: (2020)

Clinical utilization of olaparib, a PARP inhibitor, in BRCA1-mutant metastatic acral melanoma
por: Jiang, Ruixin, et al.
Publicado: (2022)

The PARP-1 inhibitor Olaparib suppresses BRCA1 protein levels, increases apoptosis and causes radiation hypersensitivity in BRCA1(+/-) lymphoblastoid cells
por: Bourton, Emma C., et al.
Publicado: (2017)

NEIL1 and NEIL2 Are Recruited as Potential Backup for OGG1 upon OGG1 Depletion or Inhibition by TH5487
por: Hanna, Bishoy M. F., et al.
Publicado: (2021)

The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells
por: Arun, Banu, et al.
Publicado: (2015)

A common SNP in the UNG gene decreases ovarian cancer risk in BRCA2 mutation carriers
por: Baquero, Juan Miguel, et al.
Publicado: (2019)

PARP1 and OGG1 in Medicated Patients With Depression and the Response to ECT
por: Ryan, Karen M, et al.
Publicado: (2022)

Targeting OGG1 arrests cancer cell proliferation by inducing replication stress
por: Visnes, Torkild, et al.
Publicado: (2020)

Genetic variation in the NEIL2 DNA glycosylase gene is associated with oxidative DNA damage in BRCA2 mutation carriers
por: Benítez-Buelga, Carlos, et al.
Publicado: (2017)

PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas
por: Czyż, Małgorzata, et al.
Publicado: (2016)

PARP-1 Expression is Increased in Colon Adenoma and Carcinoma and Correlates with OGG1
por: Dziaman, Tomasz, et al.
Publicado: (2014)

Cdh1 Deficiency Sensitizes TNBC Cells to PARP Inhibitors
por: Li, Junjun, et al.
Publicado: (2022)

Olaparib and somatic BRCA mutations
por: George, Angela, et al.
Publicado: (2017)

Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer
por: Rafii, Saeed, et al.
Publicado: (2017)

Combining Carbon-Ion Irradiation and PARP Inhibitor, Olaparib Efficiently Kills BRCA1-Mutated Triple-Negative Breast Cancer Cells
por: Kawanishi, Miki, et al.
Publicado: (2022)

DAXX, as a Tumor Suppressor, Impacts DNA Damage Repair and Sensitizes BRCA-Proficient TNBC Cells to PARP Inhibitors()
por: Shi, Yaqin, et al.
Publicado: (2019)

The PARP inhibitor Olaparib disrupts base excision repair of 5-aza-2′-deoxycytidine lesions
por: Orta, Manuel Luis, et al.
Publicado: (2014)

Olaparib‐Based Photoaffinity Probes for PARP‐1 Detection in Living Cells
por: Voorneveld, Jim, et al.
Publicado: (2020)

Anticancer activity of RAPTA-EA1 in triple-negative BRCA1 proficient breast cancer cells: single and combined treatment with the PARP inhibitor olaparib
por: Hongthong, Khwanjira, et al.
Publicado: (2021)

Nimbolide targets RNF114 to induce the trapping of PARP1 and synthetic lethality in BRCA-mutated cancer
por: Li, Peng, et al.
Publicado: (2023)

Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer
por: Lin, Z. Ping, et al.
Publicado: (2018)

An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma
por: Nile, Donna L., et al.
Publicado: (2016)

Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and Resistance
por: Singh, Desh Deepak, et al.
Publicado: (2021)

PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation
por: Mao, Yize, et al.
Publicado: (2018)

Autoimmune response to PARP and BRCA1/BRCA2 in cancer
por: Zhu, Qing, et al.
Publicado: (2015)

PARP inhibition utilized in combination therapy with Olaparib‐Temozolomide to achieve disease stabilization in a rare case of BRCA1‐mutant, metastatic myxopapillary ependymoma
por: Mahalingam, Preethika, et al.
Publicado: (2023)

Pharmacological OGG1 inhibition decreases murine allergic airway inflammation
por: Tanner, Lloyd, et al.
Publicado: (2022)

Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells
por: Sullivan-Reed, Katherine, et al.
Publicado: (2018)

Combinations of ATR, Chk1 and Wee1 Inhibitors with Olaparib Are Active in Olaparib Resistant Brca1 Proficient and Deficient Murine Ovarian Cells
por: Chiappa, Michela, et al.
Publicado: (2022)

Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells
por: Burgess, Brian T., et al.
Publicado: (2020)

Enhancing synthetic lethality of PARP-inhibitor and cisplatin in BRCA-proficient tumour cells with hyperthermia
por: Oei, Arlene L., et al.
Publicado: (2017)

Discovery of a potent olaparib–chlorambucil hybrid inhibitor of PARP1 for the treatment of cancer
por: Qin, Hongyu, et al.
Publicado: (2023)

The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
por: Ordóñez, José Luis, et al.
Publicado: (2015)

Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib
por: Nonnekens, Julie, et al.
Publicado: (2016)

PET Imaging of PARP Expression Using (18)F-Olaparib
por: Wilson, Thomas C., et al.
Publicado: (2019)

Response of BRCA1-mutated gallbladder cancer to olaparib: A case report
por: Xie, Yuan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_38mvb4qc6rvh86re2a14vmqhjo